The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC

This study is investigating new ways to detect and monitor lung squamous cell carcinoma — a type of lung cancer — using two cutting-edge technologies: a blood test that detects cancer DNA (ctDNA) and an AI-powered analysis of tissue samples. The goal is to find better tools for predicting outcomes and guiding treatment decisions after surgery. **You may be eligible if:** - You have been diagnosed with lung squamous cell carcinoma confirmed by biopsy or tissue analysis - You are between 18 and 75 years old - You have not yet received any treatment for this cancer - Your cancer is at a stage that may be surgically removable (stage II–IIIb) - Your general health is good (ECOG score 0–1) - Sufficient tissue and blood samples are available for research **You may NOT be eligible if:** - You are unable to understand or participate in the study - You do not meet health or staging requirements for surgery Talk to your doctor to see if this trial is right for you.